Pressure to make new Lundbeck drug a success rests on Peter Anastasiou
The head of Lundbeck in the USA, Peter Anastasiou, has prepared the US organization for the launch of migraine drug Vyepti at record speed. It is Lundbeck's first new launch since 2015 - and it is a big task to bear.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Lundbeck has a lot to prove with its newly-approved migraine treatment eptinezumab, which has been given the name Vyepti.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck increases research and development budget
For abonnenter
Lundbeck has potential name for migraine drug: Vyepti
For abonnenter
